EFFICACY OF BLEOMYCIN-LIPIODOL EMBOLIZATION IN TREATING SYMPTOMATIC GIANT HEPATIC VENOUS MALFORMATIONS
Bozok Tıp Dergisi · 15.06.2026 · 16 (2) · 282-292
DOI: 10.16919/bozoktip.1884924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bozok Tıp Dergisi, online erschienen am 15.06.2026. Verfasst von Mehmet Karagülle und 1 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben.
Abstract (Originalsprache)
Objective
According to the 2018 ISSVA classification, most lesions previously termed hepatic hemangiomas are now categorized as slow-flow hepatic venous malformations (HVMs). Giant HVMs (>5 cm) may cause significant symptoms and complications. To evaluate the efficacy and safety of transarterial chemoembolization (TACE) with a bleomycin-lipiodol mixture in patients with symptomatic giant hepatic venous malformations.Material and Methods: This retrospective study included 38 symptomatic patients (32 women, 6 men) with HVMs larger than 5 cm, treated between May 2020 and May 2022. Diagnosis was established using characteristic findings on contrast-enhanced computed tomography and/or magnetic resonance imaging and was supported by digital subtraction angiography. Lesion volume and symptoms were assessed pre-procedure and at 11-13 months post-treatment. Technical success was defined as selective embolization of all feeding arteries, and clinical success as symptom improvement with >50% volume reduction. Appropriate statistical analyses were performed to evaluate treatment outcomes.
Results
All procedures were technically successful. Mean baseline lesion volume decreased from 502.3 cm³ to 138.4 cm³ at one-year follow-up, a mean shrinkage of 72.4% (p<0.001). Clinical success was achieved in 94.7% of cases. Pain Visual Analog Scale scores decreased from 5.2 to 1.3 (p<0.001). No major complications occurred; three patients experienced transient post-embolization syndrome. Drug distribution grading significantly correlated with lesion shrinkage (p=0.0059), while sex, age, lesion location, and drug dose were not significant predictors.
Conclusion
Bleomycin-lipiodol TACE is a safe and effective minimally invasive treatment for symptomatic giant HVMs, achieving substantial lesion shrinkage and symptom relief with minimal complications.
Zitieren
APA
Karagülle, M., & Çakır, M. S. (2026). EFFICACY OF BLEOMYCIN-LIPIODOL EMBOLIZATION IN TREATING SYMPTOMATIC GIANT HEPATIC VENOUS MALFORMATIONS. Bozok Tıp Dergisi, 16(2), 282-292. https://doi.org/10.16919/bozoktip.1884924
Vancouver
Karagülle M, Çakır MS. EFFICACY OF BLEOMYCIN-LIPIODOL EMBOLIZATION IN TREATING SYMPTOMATIC GIANT HEPATIC VENOUS MALFORMATIONS. Bozok Tıp Dergisi. 2026;16(2):282-292. doi:10.16919/bozoktip.1884924
BibTeX
@article{Karaglle2026,
author = {Karagülle, Mehmet and Çakır, Mehmet Semih},
title = {EFFICACY OF BLEOMYCIN-LIPIODOL EMBOLIZATION IN TREATING SYMPTOMATIC GIANT HEPATIC VENOUS MALFORMATIONS},
journal = {Bozok Tıp Dergisi},
year = {2026},
volume = {16},
number = {2},
pages = {282--292},
doi = {10.16919/bozoktip.1884924}
}
EUVIMED